Renal Biomarkers Global Market Report 2024

Renal biomarkers encompass proteins, lipids, genes, metabolites, proteomic patterns, or cells that are identified through urinalysis to assess the glomerular filtration rate of the kidney. A decrease in this rate is indicative of kidney damage, and renal biomarkers are instrumental in estimating the nature and severity of such injuries.

The main types of biomarkers in renal biomarker analysis include functional biomarkers, upregulated proteins, and other biomarker categories. Functional biomarkers are particularly significant as they allow the diagnosis of kidney injury in individuals with normal kidney function and in chronic kidney disease patients where the same injury would result in a substantial decrease in functional biomarkers like creatinine (Cr). Various diagnostic techniques, such as enzyme-linked immunosorbent assay, particle-enhanced turbidimetric immunoassay (PETIA), colorimetric assay, chemiluminescent enzyme immunoassay (CLIA), and liquid chromatography-mass spectrometry (LC-MS), are employed for renal biomarker analysis. These biomarkers find applications in diagnosis, disease progression monitoring, and research, and they are utilized by hospitals, diagnostic laboratories, and other end-users.

The renal biomarker market research report is one of a series of new reports that provides renal biomarker market statistics, including renal biomarker industry global market size, regional shares, competitors with a renal biomarker market share, detailed renal biomarker market segments, market trends and opportunities, and any further data you may need to thrive in the renal biomarker industry. This renal biomarker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The renal biomarkers market size has grown strongly in recent years. It will grow from $1.17 billion in 2023 to $1.27 billion in 2024 at a compound annual growth rate (CAGR) of 8.1%. The growth observed in the historical period can be attributed to factors such as the increasing prevalence of kidney diseases, advances in medical diagnostics, an aging population, growing awareness of early disease detection, the adoption of point-of-care testing, and a rise in chronic diseases. These factors collectively contributed to the expansion of the renal biomarker market during the historic period.

The renal biomarkers market size is expected to see strong growth in the next few years. It will grow to $1.74 billion in 2028 at a compound annual growth rate (CAGR) of 8.1%. The anticipated growth in the forecast period can be attributed to factors such as the increasing focus on personalized medicine and targeted therapies, the integration of biomarker testing into routine clinical practice, the emergence of markets in Asia and Latin America, the adoption of non-invasive biomarker testing methods, and the trend toward continuous monitoring using wearable devices. Key trends expected in the forecast period encompass the use of multiplex biomarker panels for comprehensive disease profiling, the application of artificial intelligence (AI) and machine learning for biomarker discovery, the development of biomarker-based companion diagnostics, the adoption of point-of-care (POC) biomarker testing in home healthcare settings, and the use of biomarkers for early detection and prevention of diseases.

The growth of the renal biomarkers market is anticipated to be driven by the increasing prevalence of geriatric and pediatric renal patients. Geriatric renal patients, aged 70 and above, often suffer from advanced chronic kidney disease (CKD), while pediatric renal patients are typically diagnosed with renal disorders during childhood and young adulthood. Renal biomarkers play a crucial role in assessing the severity of renal injury in these patient populations. For example, data from the Centers for Disease Control and Prevention in March 2021 revealed that approximately 37 million adults in the US had chronic renal disease, with a higher prevalence in those aged 65 and older (38%). Hence, the surge in geriatric and pediatric renal patients is a key factor propelling the growth of the renal biomarkers market.

The rising incidence of chronic kidney diseases is also expected to contribute significantly to the expansion of the renal biomarkers market. Chronic kidney disease (CKD), characterized by the gradual loss of kidney function, has witnessed an increased prevalence over time. Renal biomarkers play a crucial role in identifying and monitoring CKD progression, enabling timely interventions and personalized treatment strategies. Notably, data from the Centers for Medicare & Medicaid Services in March 2022 indicated an increase in CKD prevalence from 15% in 2012 to 25% in 2020, with diabetes and hypertension identified as the primary causes. Thus, the growing occurrence of chronic kidney diseases is a key driver for the renal biomarkers market.

The renal biomarkers market is witnessing a key trend with technological advancements playing a pivotal role. Major players in the sector are focusing on innovative technologies to maintain their market position. For instance, RenalytixAI, a UK-based developer of AI-enabled clinical diagnostic solutions for kidney disease, collaborated with DaVita to develop KidneyIntelX in January 2021. KidneyIntelX, powered by artificial intelligence, serves as a diagnostic tool to identify individuals at risk of renal disease or kidney failure. By utilizing a machine-learning algorithm, KidneyIntelX produces a patient-specific risk assessment based on blood biomarkers and electronic medical information.

Strategic collaborations and partnerships with start-ups and mid-sized companies are becoming increasingly prevalent in the renal biomarkers market. This approach allows major companies to expand their product and service offerings. In June 2022, Nordic Bioscience, a Denmark-based biomarker company, strengthened its collaboration with F. Hoffmann-La Roche Ltd., a multinational healthcare company. This collaboration involves the development of proprietary biomarkers related to tissue breakdown and build-up. Nordic Bioscience's ECM biomarkers are deemed essential for various chronic diseases, including kidney diseases. The partnership aims to improve clinical decisions in drug development and patient selection, ultimately enhancing patient outcomes.

In April 2021, Renalytix AI, a US-based biotechnology research company, partnered with the Joslin Diabetes Center to integrate new biomarkers for chronic kidney disease. This collaboration allows the incorporation of novel biomarkers into Renalytix's KidneyIntelX, enhancing the indicators collected for individuals with Type 2 diabetes and early kidney disease. The Joslin Diabetes Center, based in the US, is a renowned diabetes research center and clinic.

Major companies operating in the renal biomarkers market include Abbott Laboratories, BioPorto Diagnostics A/S, Roche Holding AG, Thermo Fisher Scientific, bioMérieux SA, Randox Laboratories, Siemens Healthineers, Beckman Coulter Inc., Astute Medical Inc., Nexelis Company, Sphingotec GmbH, Bio-Rad Laboratories India Pvt. Ltd., Enzo Biochem Inc., PerkinElmer Inc., Novartis AG, Eli Lilly and Company, Alere Inc., AstraZeneca PLC, Bio-Techne Corp., DiaSorin S.p.A., EKF Diagnostics Holdings PLC, Fujirebio Diagnostics Inc., Gold Standard Diagnostics Corp., Merck KGaA, Myriad RBM Inc., Ortho Clinical Diagnostics Holdings PLC, Quidel Corporation, R&D Systems Inc., Roche Diagnostics International Ltd ., Sekisui Chemical Co. Ltd., Sysmex Corporation, Tosoh Bioscience Inc.

North America was the largest region in the renal biomarkers market in 2023. Asia-Pacific is expected to be the fastest-growing region during the forecast period. The regions covered in the renal biomarkers market analysis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the renal biomarkers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The renal biomarker market consists of revenues earned by entities by providing renal biomarker services such as integrated drug discovery, phenotypic assay, custom services, in vivo, biomarker identification, glomerular filtration diagnosis. The market value includes the value of related goods sold by the service provider or included within the service offering. The renal biomarker market also includes sales of point-of-care kit, antibody screening, cell-based diagnostic devices which are used in providing renal biomarker services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.